Last reviewed · How we verify
GLPG1837 dose 1
At a glance
| Generic name | GLPG1837 dose 1 |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (PHASE2)
- Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) (PHASE2)
- A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG1837 dose 1 CI brief — competitive landscape report
- GLPG1837 dose 1 updates RSS · CI watch RSS
- Galapagos NV portfolio CI